About Pierrel

Pierrel S.p.A. is a global provider to the pharmaceutical and life science industries, specialized specialized in clinical development, registration and licensing of new drugs or formulations and in pharmaceutical production ,  through its Contract Research ,  Contract Manufacturing and  Pharma Divisions.

Pierrel Group, with over 60 years of experience in the pharmaceutical sector, is one of the main European manufacturers of local and dental anesthetic drug products. Pierrel SpA is listed on  the Italian Stock Exchange market since 2006 More.

Pierrel Pharma S.r.l. is responsible for sales and marketing of Orabloc in the US and Canada through a network of established and respected distributors of dental products More. 

Orabloc— A New Articaine in the USA

• Rapid onset of anestesia within 1-9 minutes
• Complete anesthesia lasts about 1 hour for infiltration, up to 2 hours for nerve block
• Only 10% overage of epinephrine1
• A 24 month shelf life at room temperature
• Very low manufacture related degradation products such as articaine acid and epinephrine sulphonic acid
• Sodium edentate free, methylparaben free and latex free
• Each Orabloc^TM individual cartridge is blister packed for maximum protection during storage and handling

WARNING AND PRECAUTIONS

Orabloc^TM is an amide local anesthetic containing a vasoconstrictor indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.

Orabloc^TM contains sodium metabisulfite. Orabloc^TM is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

REFERENCES:

¹The American Heart Association (AHA) reccomends using the lowest possible quantity of epinephrine (Kaplan EL ed. Cardiovascular disease in dental practice. Dallas, TX: American Heart Association, 1986.)